1. Boxer LA, Newburger PE. A molecular classification
of congenital neutropenia syndromes. Pediatr Blood Cancer. 2007;49(5):609-614.
2. Bertrand Y, Muller SM, Casanova JL, Morgan G, Fischer A,
Friedrich W. Reticular dysgenesis: HLA non-identical bone marrow
transplants in a series of 10 patients. Bone Marrow Transplant. 2002;29(9):759-762.
3. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency:
genetic, phenotypic, and functional diversity in one hundred eight
infants. J Pediatr. 1997;130(3): 378-387.
4. Stephan JL, Vlekova V, Le Deist F, et al. Severe combined
immunodeficiency: a retrospective single-center study of clinical
presentation and outcome in 117 patients. J Pediatr. 1993;123(4):
564-572.
5. Dale DC, Hammond WPT. Cyclic neutropenia: a clinical review. Blood
Rev. 1988;2(3):178-185.
6. Dale DC, Person RE, Bolyard AA, et al. Mutations in the gene encoding
neutrophil elastase in congenital and cyclic neutropenia. Blood. 2000;96(7):2317-2322.
7. Ochs HD. Primary Immunodeficiency Diseases: A Molecular
and Genetic Approach. New York: Oxford University Press;
2006.
8. Palmer SE, Stephens K, Dale DC. Genetics, phenotype, and
natural history of autosomal dominant cyclic hematopoiesis. Am
J Med Genet. 1996;66(4):413-422.
9. Boxer LA, Stein S, Buckley D, Bolyard AA, Dale DC. Strong
evidence for autosomal dominant inheritance of severe congenital neutropenia
associated with ELA2 mutations. J Pediatr. 2006;148(5):633-636.
10. Carlsson G, Aprikyan AA, Tehranchi R, et al. Kostmann syndrome:
severe congenital neutropenia associated with defective expression
of Bcl-2, constitutive mitochondrial release of cytochrome c, and
excessive apoptosis of myeloid progenitor cells. Blood. 2004;103(9):3355-3361.
11. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia:
treatment and follow-up of patients in the Severe Chronic Neutropenia
International Registry. Am J Hematol. 2003;72(2):82-93.
12. Boxer L, Dale DC. Neutropenia: causes and consequences. Semin
Hematol. 2002;39(2):75-81.
13. Skokowa J, Germeshausen M, Zeidler C, Welte K. Severe congenital
neutropenia: inheritance and pathophysiology. Curr Opin
Hematol. 2007;14 (1):22-28.
14. Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency
causes autosomal recessive severe congenital neutropenia (Kostmann
disease). Nat Genet. 2007;39(1):86-92.
15. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled
phase III trial of recombinant human granulocyte colony-stimulating
factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81(10):2496-2502.
16. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence
of leukemia and mortality from sepsis in patients with severe congenital
neutropenia receiving long-term G-CSF therapy. Blood. 2006;107(12):4628-4635.
17. Dror Y, Freedman MH. Shwachman-diamond syndrome. Br
J Haematol. 2002;118(3):701-713.
18. Boocock GR, Morrison JA, Popovic M, et al. Mutations in SBDS
are associated with Shwachman-Diamond syndrome.
Nat Genet. 2003;
33(1):97-101.
[PubMed: 12496757]
19. Shimamura A. Shwachman-Diamond syndrome. Semin Hematol. 2006;43(3):178-188.
20. Dokal I. Dyskeratosis congenita in all its forms. Br
J Haematol. 2000;110(4):768-779.
21. Mason PJ, Wilson DB, Bessler M. Dyskeratosis congenita—a
disease of dysfunctional telomere maintenance. Curr Mol
Med. 2005;5(2):159-170.
22. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal
I. Mutations in dyskeratosis congenita: their impact on telomere
length and the diversity of clinical presentation. Blood. 2006;107(7):2680-2685.
23. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A,
Dokal I. Mutations in the reverse transcriptase component of telomerase
(TERT) in patients with bone marrow failure. Blood Cells
Mol Dis. 2005;34(3):257-263.
24. Barth PG, Valianpour F, Bowen VM, et al. X-linked cardioskeletal
myopathy and neutropenia (Barth syndrome): an update. Am
J Med Genet A. 2004;126(4):349-354.
25. Barth PG, Wanders RJ, Vreken P, Janssen EA, Lam J, Baas
F. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM
302060). J Inherit Metab Dis. 1999;22(4):555-567.
26. Cormier V, Rotig A, Quartino AR, et al. Widespread multi-tissue deletions
of the mitochondrial genome in the Pearson marrow-pancreas syndrome. J
Pediatr. 1990;117(4):599-602.
27. McShane MA, Hammans SR, Sweeney M, et al. Pearson syndrome
and mitochondrial encephalomyopathy in a patient with a deletion
of mtDNA. Am J Hum Genet. 1991;48(1):39-42.
28. Melis D, Fulceri R, Parenti G, et al. Genotype/phenotype
correlation in glycogen storage disease type 1b: a multicentre study
and review of the literature. Eur J Pediatr. 2005;164(8):501-508.
29. Kuijpers TW, Maianski NA, Tool AT, et al. Apoptotic neutrophils
in the circulation of patients with glycogen storage disease type 1b
(GSD1b). Blood. 2003;101(12):5021-5024.
30. Borregaard N, Boxer LA. Disorders of neutrophil function.
In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal
JT, eds. Williams Hematology. 7th ed. New York:
McGraw-Hill Medical Publishing Division; 2006:921-957.
31. Barbosa MD, Barrat FJ, Tchernev VT, et al. Identification
of mutations in two major mRNA isoforms of the Chediak-Higashi syndrome
gene in human and mouse. Hum Mol Genet. 1997;6(7):1091-1098.
32. Spritz RA. Multi-organellar disorders of pigmentation: tied
up in traffic. Clin Genet. 1999;55(5):309-317.
33. Barton LM, Roberts P, Trantou V, Haworth C, Kelsey H, Blamires T.
Chédiak-Higashi syndrome.
Br J Haematol. 2004;125(1):2.
[PubMed: 15015961]
34. Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog
C, Prunieras M. A syndrome associating partial albinism and immunodeficiency. Am
J Med. 1978;65(4):691-702.
35. Menasche G, Pastural E, Feldmann J, et al. Mutations in RAB27A
cause Griscelli syndrome associated with haemophagocytic syndrome. Nat
Genet. 2000;25(2):173-176.
36. Fontana S, Parolini S, Vermi W, et al. Innate immunity defects in
Hermansky-Pudlak type 2 syndrome. Blood. 2006;107(12):4857-4864.
37. Jung J, Bohn G, Allroth A, et al. Identification of a homozygous deletion
in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood. 2006;108(1):362-369.
38. Bohn G, Allroth A, Brandes G, et al. A novel human primary
immunodeficiency syndrome caused by deficiency of the endosomal adaptor
protein p14. Nat Med. 2007;13(1):38-45.
39. Kolehmainen J, Wilkinson R, Lehesjoki AE, et al. Delineation
of Cohen syndrome following a large-scale genotype-phenotype screen. Am
J Hum Genet. 2004;75(1):122-127.
40. Buckley RH. Primary immunodeficiency diseases due to defects in
lymphocytes. N Engl J Med. 2000;343(18):1313-1324.
41. Hermanns P, Tran A, Munivez E, et al. RMRP mutations in
cartilage-hair hypoplasia. Am J Med Genet A. 2006;140(19):2121-2130.
42. Durandy A, Peron S, Fischer A. Hyper-IgM syndromes. Curr
Opin Rheumatol. 2006;18(4):369-376.
43. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum
of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1
Pt 1):47-54.
44. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations
in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood. 2006;108(7):2182-2189.
45. O’Regan S, Newman AJ, Graham RC. “Myelokathexis.” Neutropenia
with marrow hyperplasia. Am J Dis Child. 1977;131(6):655-658.
46. Zuelzer WW. “Myelokathexis”—a
new form of chronic granulocytopenia. Report of a case.
N
Engl J Med. 1964;270:699-704.
[PubMed: 14101065]
47. Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with
different genetic anomalies are accounted for by impaired CXCR4
desensitization to CXCL12. Blood. 2005;105(6):2449-2457.
48. Weetman RM, Boxer LA. Childhood neutropenia. Pediatr
Clin North Am. 1980;27(2):361-376.
49. Boxer LA, Yokoyama M, Lalezari P. Isoimmune neonatal neutropenia. J
Pediatr. 1972;80(5): 783-787.
50. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical
course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood. 1998;91(1):
181-186.
51. Bruin MC, von dem Borne AE, Tamminga RY, Kleijer M, Buddelmeijer
L, de Haas M. Neutrophil antibody specificity in different types
of childhood autoimmune neutropenia. Blood. 1999;94(5):1797-1802.
52. Palmblad J, Papadaki HA, Eliopoulos G. Acute and chronic neutropenias.
What is new? J Intern Med. 2001;250(6):476-491.
53. Ivanovich PP, Chenoweth DDE, Schmidt RR, et al. Symptoms
and activation of granulocytes and complement with two dialysis
membranes. Kidney Intl. 1983;24(6):758-763.
54. Smith CW. Production, distribution, and fate of neutrophils.
In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K,
Prchal JT, eds. Williams Hematology. 7th ed. New
York: McGraw-Hill Medical Publishing Division; 2006:855-861.
55. Khanna-Gupta A, Sun H, Zibello T, et al. Growth factor independence-1
(Gfi-1) plays a role in mediating specific granule deficiency (SGD)
in a patient lacking a gene-inactivating mutation in the C/EBPepsilon
gene. Blood. 2007;109(10):4181-4190.
56. Lekstrom-Himes JA, Dorman SE, Kopar P, Holland SM, Gallin JI.
Neutrophil-specific granule deficiency results from a novel mutation
with loss of function of the transcription factor CCAAT/enhancer
binding protein epsilon. J Exp Med. 1999;189(11):1847-1852.
57. Anderson DC, Schmalsteig FC, Finegold MJ, et al. The severe and
moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their
quantitative definition and relation to leukocyte dysfunction and
clinical features. J Infect Dis. 1985;152(4):668-689.
58. Etzioni A. Leukocyte adhesion deficiencies: molecular basis,
clinical findings, and therapeutic options.
Adv Exp Med
Biol. 2007;601:51-60.
[PubMed: 17712991]
59. Helmus Y, Denecke J, Yakubenia S, et al. Leukocyte adhesion
deficiency II patients with a dual defect of the GDP-fucose transporter. Blood. 2006;107(10):3959-3966.
60. Yakubenia S, Wild MK. Leukocyte adhesion deficiency II.
Advances and open questions. FEBS J. 2006;273(19):4390-4398.
61. Kinashi T, Aker M, Sokolovsky-Eisenberg M, et al. LAD-III,
a leukocyte adhesion deficiency syndrome associated with defective
Rap1 activation and impaired stabilization of integrin bonds. Blood. 2004;103(3):1033-1036.
62. Malech HL, Hickstein DD. Genetics, biology and clinical management
of myeloid cell primary immune deficiencies: chronic granulomatous
disease and leukocyte adhesion deficiency. Curr Opin Hematol. 2007;14(1):29-36.
63. Erlewyn-Lajeunesse MD. Hyperimmunoglobulin-E syndrome with
recurrent infection: a review of current opinion and treatment. Pediatr
Allergy Immunol. 2000;11(3):133-141.
64. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome
with recurrent infections—an autosomal dominant multisystem
disorder. N Engl J Med. 1999;340(9):692-702.
65. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes.
Immunol
Rev. 2005;203:244-250.
[PubMed: 15661034]
66. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations
in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608-1619.
67. Johnston RB Jr. Clinical aspects of chronic granulomatous
disease. Curr Opin Hematol. 2001;8 (1):17-22.
68. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic,
biochemical, and clinical features of chronic granulomatous disease. Medicine
(Baltimore). 2000;79(3):170-200.
69. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous
disease. Report on a national registry of 368 patients. Medicine
(Baltimore). 2000;79(3):155-169.
70. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr
Opin Immunol. 2003;15(5):578-584.
71. Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency
syndrome is associated with an inhibitory Rac2 mutation. Proc
Natl Acad Sci USA. 2000;97(9):4654-4659.
72. Williams DA, Tao W, Yang F, et al. Dominant negative mutation of
the hematopoietic-specific Rho GTPase, Rac2, is associated with
a human phagocyte immunodeficiency. Blood. 2000;96
(5):1646-1654.
73. A controlled trial of interferon gamma to prevent infection
in chronic granulomatous disease. The International Chronic Granulomatous
Disease Cooperative Study Group. N Engl J Med. 1991;
324(8):509-516.
74. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to
prevent fungal infections in chronic granulomatous disease. N
Engl J Med. 2003;348(24): 2416-2422.
75. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of
X-linked chronic granulomatous disease by gene therapy, augmented
by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat
Med. 2006;12(4):401-409.
76. Boxer LA, Blackwood RA. Leukocyte disorders: quantitative and
qualitative disorders of the neutrophil, part 2. Pediatr
Rev. 1996;17(2):47-50.
77. Kutter D. Prevalence of myeloperoxidase deficiency: population
studies using Bayer-Technicon automated hematology.
J Mol
Med. 1998; 76(10):669-675.
[PubMed: 9766844]
78. Brown L, Shaw T, Wittlake WA. Does leucocytosis identify bacterial
infections in febrile neonates presenting to the emergency department? Emerg
Med J. 2005;22(4):256-259.
79. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins
Pathologic Basis of Disease. 6th ed. Philadelphia: WB Saunders;
1999.
80. Dinauer MC. The phagocyte system and disorders of granulopoiesis
and granulocyte function. In: Nathan DG, Oski SH, eds. Nathan
and Oski’s Hematology of Infancy and Childhood. Vol
1. 5th ed. Philadelphia: WB Saunders; 1998:889.
81. Shah SS, Shofer FS, Seidel JS, Baren JM. Significance of
extreme leukocytosis in the evaluation of febrile children. Pediatr
Infect Dis J. 2005;24 (7):627-630.
82. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. IV.
The total blood, circulating and marginal granulocyte pools and
the granulocyte turnover rate in normal subjects.
J Clin
Invest. 1961;40:989-995.
[PubMed: 13684958]
83. Herring WB, Smith LG, Walker RI, Herion JC. Hereditary neutrophilia. Am
J Med. 1974;56 (5):729-734.
84. Lichtman MA. Monocytosis and monocytopenia. In: Lichtman MA,
Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams
Hematology. 7th ed. New York: McGraw-Hill Medical Publishing
Division; 2006:987-991.
85. Kipps TJ. Lymphocytosis and lymphocytopenia. In: Lichtman MA,
Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams
Hematology. 7th ed. New York: McGraw-Hill Medical Publishing
Division; 2006:1087-1097.
86. otlib J. Molecular classification and pathogenesis of eosinophilic
disorders: 2005 update. Acta Haematol. 2005;114(1):7-25.
87. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta
Haematol. 2005;114 (1):52-60.
88. Weller PF. Eosinophilia in travelers. Med Clin North
Am. 1992;76(6):1413-1432.
89. Galli SJ, Metcalfe DD, Arber DA, Dvorak AM. Basophils and mast
cells and their disorders. In: Lichtman MA, Beutler E, Kipps TJ,
Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology.
7th ed. New York: McGraw-Hill Medical Publishing Division; 2006:879-897.